NASDAQ:AGEN - Agenus Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.62 +0.43 (+13.48 %) (As of 01/17/2019 11:39 AM ET)Previous Close$3.19Today's Range$3.23 - $3.6952-Week Range$1.54 - $6.19Volume105,081 shsAverage Volume3.23 million shsMarket Capitalization$376.79 millionP/E Ratio-2.92Dividend YieldN/ABeta1.98 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Receive AGEN News and Ratings via Email Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:AGEN Previous Symbol CUSIP00847G70 Webagenusbio.com Phone781-674-4400Debt Debt-to-Equity RatioN/A Current Ratio1.16 Quick Ratio1.16Price-To-Earnings Trailing P/E Ratio-2.92 Forward P/E Ratio-2.68 P/E GrowthN/A Sales & Book Value Annual Sales$42.88 million Price / Sales10.13 Cash FlowN/A Price / Cash FlowN/A Book Value($0.74) per share Price / Book-4.89Profitability EPS (Most Recent Fiscal Year)($1.23) Net Income$-120,690,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-103.43%Miscellaneous Employees255 Outstanding Shares120,000,000Market Cap$376.79 million OptionableOptionable Agenus (NASDAQ:AGEN) Frequently Asked Questions What is Agenus' stock symbol? Agenus trades on the NASDAQ under the ticker symbol "AGEN." How were Agenus' earnings last quarter? Agenus Inc (NASDAQ:AGEN) posted its quarterly earnings data on Tuesday, November, 6th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.04. The biotechnology company earned $12.80 million during the quarter, compared to the consensus estimate of $10.76 million. View Agenus' Earnings History. When is Agenus' next earnings date? Agenus is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Agenus. Has Agenus been receiving favorable news coverage? Media headlines about AGEN stock have been trending positive this week, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Agenus earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an impact on the company's share price in the next few days. Who are some of Agenus' key competitors? Some companies that are related to Agenus include Editas Medicine (EDIT), Autolus Therapeutics (AUTL), Rubius Therapeutics (RUBY), Iovance Biotherapeutics (IOVA), Sangamo Therapeutics (SGMO), Orchard Therapeutics (ORTX), Momenta Pharmaceuticals (MNTA), Fate Therapeutics (FATE), Solid Biosciences (SLDB), Audentes Therapeutics (BOLD), BioCryst Pharmaceuticals (BCRX), Coherus Biosciences (CHRS), Novavax (NVAX), Acorda Therapeutics (ACOR) and Vericel (VCEL). Who are Agenus' key executives? Agenus' management team includes the folowing people: Dr. Garo H. Armen, Founder, Exec. Chairman & CEO (Age 66)Ms. Christine M. Klaskin, Principal Accounting Officer & VP of Fin. (Age 53)Dr. Alexander R. Duncan, CTO & Head of Research (Age 57)Dr. Robert B. Stein, Sr. R&D Advisor (Age 68)Dr. Christian Cortis, Chief Strategy Officer & Head of Fin. (Age 51) Who are Agenus' major shareholders? Agenus' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.03%). Company insiders that own Agenus stock include Alex Duncan, Christine M Klaskin, Corp Incyte, Garo H Armen and Karen Valentine. View Institutional Ownership Trends for Agenus. Which institutional investors are selling Agenus stock? AGEN stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for Agenus. How do I buy shares of Agenus? Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Agenus' stock price today? One share of AGEN stock can currently be purchased for approximately $3.57. How big of a company is Agenus? Agenus has a market capitalization of $376.79 million and generates $42.88 million in revenue each year. The biotechnology company earns $-120,690,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Agenus employs 255 workers across the globe. What is Agenus' official website? The official website for Agenus is http://agenusbio.com. How can I contact Agenus? Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected] MarketBeat Community Rating for Agenus (NASDAQ AGEN)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 350 (Vote Outperform)Underperform Votes: 248 (Vote Underperform)Total Votes: 598MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2019 by MarketBeat.com StaffFeatured Article: How Do Investors Open a Backdoor Roth IRA?